# Olaparib with or without radiation in inflammatory breast cancer

Source: https://onco.cc/trials/nct03598257/  
OnCo record `nct03598257` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests whether adding olaparib improves radiation treatment for inflammatory breast cancer. It is not accepting new participants.

## Summary

Registry status active not recruiting, last updated 2026-09-29. Enrollment is 300 estimated. Non-metastatic inflammatory breast cancer of any receptor subtype after neoadjuvant chemotherapy and modified radical mastectomy with negative margins and axillary evaluation. Randomized radiation with or without olaparib; positive microscopic margins or gross residual tumour after mastectomy are excluded. This disease-specific protocol must not be presented as general postoperative TNBC enrollment.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Registry id: NCT03598257
- Phase: 2
- Setting: Non-metastatic inflammatory breast cancer of any receptor subtype after neoadjuvant chemotherapy and modified radical mastectomy with negative margins and axillary evaluation
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT03598257: https://clinicaltrials.gov/study/NCT03598257

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)

---
JSON: https://onco.cc/api/v1/entities/nct03598257.json